CuraVac was created to develop the medical and commercial potential of a newly discovered technique for the production of therapeutic vaccines for the treatment of autoimmune diseases.

The company was founded by a Belgian medical doctor, Dr. Stéphane Huberty - who himself is a sufferer from myasthenia gravis. The original discoverer of the vaccine production technique, Professor J Edwin Blalock is a consultant to CuraVac.

The production technique for the vaccines and the MG vaccine is patented and the first vaccine is ready for preliminary, Phase 1, human trials. Currently CuraVac is raising funds to cover the costs of Phase 1 and Phase 2 clinical trials.

This vaccine is the first in a series. It will be tested on humans suffering from myasthenia gravis (MG). While not widely known, MG affects more than one in seven thousand and its pathology is clearly understood, making it an excellent development model.

Further, CuraVac therapeutic vaccines will be developed for the treatment of other autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis and systemic lupus erythematosis. In total, autoimmune diseases afflict around three percent of western population.